Tag

AnaptysBio Inc.

1 article

AnaptysBio Q2 Loss 13¢, Revenue Down 21%

Analysts expect Q2 loss of $0.13 per share on revenue $20.2 million, a 21% sequential decline from $25.6 million. Jemperli royalties rose 44% to $24.7 million in Q1, boosted by FDA acceptance for prio